Sign in →

Test Code CLD18 Claudin 18 (CLDN18) (43-14A), Semi-Quantitative Immunohistochemistry, Manual


Shipping Instructions


Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.



Necessary Information


A pathology/diagnostic report and a brief history are required.



Specimen Required


Specimen Type: Tissue

Supplies: Pathology Packaging Kit (T554)

Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue

Additional Information: One slide will be stained with hematoxylin and eosin and returned.


Secondary ID

620665

Useful For

Identification of tumor cells expressing claudin 18

 

As an aid in screening patients who may be eligible for VYLOY (zolbetuximab) treatment

Method Name

Immunohistochemistry (IHC)

Reporting Name

CLDN18, SemiQuant IHC, Manual

Specimen Type

Special

Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)
  Refrigerated 

Reject Due To

Decalcified paraffin embedded tissue
Wet/frozen tissue
Cytology smears
Nonformalin fixed tissue including alcohol-formalin-acetic acid (AFA), 95% ethanol, PREFER fixatives or Zinc formalin
Nonparaffin embedded tissue
Noncharged slides
ProbeOn slides
Reject

Clinical Information

Claudin 18 (CLDN18) is a member of the claudin protein family that regulates cell adhesion. A qualitative immunohistochemistry assessment using mouse monoclonal anti-claudin 18, clone 43-14A, serves as a biomarker in gastric and gastroesophageal junction cancer and may aid in identifying patients eligible for VYLOY (zolbetuximab) treatment.

Reference Values

An interpretive report will be provided.

Interpretation

Claudin 18.2 is a biomarker for gastric and gastroesophageal junction cancer. When positive (defined as at least moderate membranous staining in greater than or equal to 75% of viable tumor cells), it predicts response to zolbetuximab which has been approved for the treatment of gastric and gastroesophageal adenocarcinoma.

Method Description

Immunoperoxidase staining and detection of Claudin 18 (CLDN18) is performed in formalin-fixed, paraffin-embedded tissue sections using the VENTANA CLDN18 (43-14A) RxDx Assay. The 4-micron tissue sections are deparaffinized, subjected to heat-induced antigen retrieval and peroxidase inhibitor, incubated with a monoclonal antibody (clone 43-14A), and visualized using a proprietary kit detection system. Sections are counterstained with hematoxylin. Stained slides are examined microscopically by the consulting anatomic pathologist.(Package insert: VENTANA CLDN18 (43-14A) RxDx Assay. Ventana Medical Systems, Inc.; 1016387US Rev A, 10/11/2024)

 

Results are interpreted using the manufacturer-provided interpretation guide.(Instruction manual: VENTANA CLDN18 (43-14A) RxDx Assay Interpretation Guide for Gastric Adenocarcinoma including Gastroesophageal Junction (GEJ). Ventana Medical Systems, Inc.; 1021576EN Rev B, 10/01/2024)

Day(s) Performed

Monday through Friday

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88360

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CLD18 CLDN18, SemiQuant IHC, Manual 105011-1

 

Result ID Test Result Name Result LOINC Value
620666 Interpretation 50595-8
621004 Participated in the Interpretation No LOINC Needed
621005 Report electronically signed by 19139-5
621006 Material Received 81178-6
621007 Disclaimer 62364-5
621008 Case Number 80398-1

Forms

If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.